When the population PK of etrolizumab in patients with moderately-to-severely active UC was described (two-compartment model with first-order absorption and elimination), a decrease in clearance was established over the first months of treatment and etrolizumab exposure was found to be impacted by baseline albumin (in addition to body weight) – this may potentially reflect decreasing inflammation with time, although the available samples of time-varying albumin was not found to be superior in explaining the pattern over time.
Find the publication here:
Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis
Pharmetheus affiliates:
Siv Jönsson – Siv’s publications
Jakob Ribbing – Jakob’s publications
